Article

Examining How HIV Ages Patients

Researchers look to determine why young HIV patients exhibit illnesses commonly associated with older people, despite all the progress that has been made.

Through the development of antiretroviral therapy, many patients with HIV are living much longer than they did in the early years of the AIDS epidemic; in fact, it is estimated that by 2015, about half of all HIV-positive individuals will be older than 50.

Yet those over 50 also progress to AIDS faster than adults in their 20s or 30s. And those in the younger age bracket—even those responding well to antiretroviral therapy—still exhibit illnesses and clinical conditions commonly associated with older people, such as certain cancers and liver diseases. For the most part, the reasons for this have remained a mystery.

A UCLA AIDS Institute study published in the online journal PLoS ONE suggests a partial explanation, showing that HIV causes a specific subset of CD4 "helper" T-cells to age rapidly, by as much as 20 to 30 years over a three-year period.

In the study, researchers witnessed a decline in CD4 T-cell numbers, and found that in the surviving T-cells, the HIV virus caused rapid and drastic shortening of the ends of telomeres, which protect the chromosomes and prevent them from fusing together.

"Our findings have important implications for the health of both young and old HIV-1—infected adults," said lead investigator Tammy M. Rickabaugh of the David Geffen School of Medicine at UCLA, in a press release. "They underscore the importance of developing new approaches to boost immune function to complement current treatments, which are exclusively directed against the virus."

The researchers examined two subsets of CD4 T-cells (CD45RA CD31 and CD45RA CD31-) in two groups of individuals—those aged 20-32 and those aged 39-58—who had been infected with HIV for one to three years and who had not been treated with antiretroviral therapy. They compared these two groups with samples from age-matched controls who were HIV seronegative.

The researchers specifically focused on naive T-cells, and found that in individuals infected with HIV-1, these cells underwent unexpectedly rapid aging. They also found that the number of CD31- T-cells, which are more quickly pulled into the fight against new pathogens, had fallen drastically.

The researchers also investigated whether appropriate treatment could reverse this aging effect. They examined cells from HIV-positive individuals who had been on antiretroviral therapy for two years and whose therapy had successfully kept HIV-1 under control. They determined that while the therapy kept their viral loads at undetectable levels, it did not entirely restore their immune systems, suggesting a reason why younger HIV-positive people still become ill with conditions more common to older people.

"Taken together, our results help to explain some of the clinical observations that have been documented in HIV-infected people and emphasize the need for developing therapeutic approaches directed at improving the naive immune cell compartment," said senior investigator Beth D. Jamieson, PhD. "This is critically important in light of the demographic shift of HIV-infected persons."

For more:

  • The Dual Impact of HIV-1 Infection and Aging on Naïve CD4 T-Cells: Additive and Distinct Patterns of Impairment
  • What HIV Quality Care Measures Mean for Your Practice
  • World AIDS Day 2010
Related Videos
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
A Year of RSV Highs and Lows, with Tina Tan, MD
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Mikkael Sekeres, MD:
© 2024 MJH Life Sciences

All rights reserved.